<DOC>
	<DOC>NCT03001882</DOC>
	<brief_summary>The purpose of this study is to explore the possible links between patient characteristics and their cancer, with how effective the combination of nivolumab with ipilimumab is, in patients with Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC).</brief_summary>
	<brief_title>An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Histologically confirmed, stage IV or recurrent nonsmall cell lung cancer with no prior systemic anticancer therapy given as primary therapy for advanced or metastatic disease Measurable disease by CT or MRI Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work Patients with untreated central nervous system metastases Participants with active, known or suspected autoimmune disease Prior treatment with any drug that targets T cell costimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>